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Infection in those with hydrocephalus shunts or external drains (EVDs) can 
cause serious central nervous system damage with lasting sequelae. The infections 
usually involve bacterial colonisation and biofilm formation in the catheters. The 
nature and sources of pathogens and preventive measures are discussed. The risks 
of infection in shunts and EVDs is different. Infection in shunts is almost always 
initiated at their insertion or revision (exceptions are described). In contrast, in 
EVDs, the risk of infection persists throughout their use. The pathogen profile is 
also different. These factors are important considerations when planning preventive 
measures. Newer strategies such as antimicrobial catheters are discussed. Diagnosis 
of EVD infections in an already ill patient is difficult but guidelines can be useful. 
Treatment of the shunt and EVD infections are also addressed, with reference to 
modes and routes of antibiotic administration.
Keywords: Hydrocephalus, shunt, external ventricular drain, infection, biofilm, 
diagnosis, treatment, prevention, prophylactic antibiotics, antimicrobial catheters
1. Introduction
Though several historical attempts had been made to drain excess cerebrospinal 
fluid (CSF) in cases of hydrocephalus, this remained largely unsuccessful until the 
advent of valved shunting devices in the 1950’s in USA. More recently endoscopic 
third ventriculostomy has been used in selected patients, but shunting is still the 
usual method of treatment of hydrocephalus. In patients with raised intracranial 
pressure due to trauma, malignancy or haemorrhage, where it is hoped the situation 
is temporary, external ventricular drainage (EVD) is often used. This temporary 
method of control of intracranial pressure is also used after shunt removal for 
infection, before insertion of a new shunt. The risks for infection in the two modes 
of treatment are different.
Infection in shunts appeared soon after they became more widely used [1], 
though for some time their cause and treatment remained poorly understood, until it 
was realised in the early 1970’s that most were caused by a bacterium, Staphylococcus 
epidermidis, that hitherto had been considered a harmless commensal and common 
culture contaminant [2]. The mechanisms of infection and reasons for difficulty in 
treatment have been clarified over the subsequent decades.
EVD has a very long history, but infection remained a major problem until the 
introduction of sterile closed systems of drainage in 1941 [3]. It is still a matter of 
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concern and more recent increases in infections due to multi-drug-resistant (MDR) 
bacteria have exacerbated this.
Infections in shunts lead to repeated operations and courses of antibiotics and 
can lead to further cognitive impairment. Infections in EVDs lead to longer hospital 
stay, courses of antibiotics, and worse overall neurosurgical outcomes. In both cases 
death can result. Prompt diagnosis and appropriate treatment are essential, and 
prevention should be the primary goal. These can be achieved best with an under-
standing of the underlying science.
2. Aetiology and incidence
Infection rates have fallen in both shunting and EVD since the 1970’s when 
up to 23% of shunts were reported as becoming infected [4, 5]. More recent rates 
for shunt infection have been below 10%, with 6% reported in a clinical trial [6]. 
However, it has been clear for some time that the infection rate in infants shunted 
when less than 6 months of age is significantly higher [7, 8] sometimes approaching 
15–20% of operations [9].
The reported infection rate in EVDs is very variable, mainly due to difficulties 
in diagnosis, diagnostic criteria used and significant differences in underlying 
pathologies between patient groups studied. Earlier studies reported higher rates, 
15–23% [10, 11] while slightly later studies reported 7.5% more in keeping with our 
own observations [12, 13].
2.1 Causative organisms in shunt infection
Since the first reports of shunt infection, staphylococci have predominated 
in shunt infection, with the majority being coagulase – negative staphylococci 
(CoNS). Of these, most are Staphylococcus epidermidis. A minority of staphylococci 
are Staphylococcus aureus. The proportion of these that are methicillin- resistant 
(MRSA) varies between countries according to national MRSA epidemiology 
[14], but in most countries especially The Netherlands, Scandinavia and United 
Kingdom, the proportion of MRSA in shunt infections is low [15]. However, methi-
cillin resistance in CoNS is now common [16, 17]. Another important shunt patho-
gen is Cutibacterium (Propionibacterium) acnes [18, 19], found mainly in adolescents 
and adults. This bacterium is under-reported and probably accounts for some of 
the “culture-negative” shunt infections, as it is anaerobic and slow-growing, taking 
up to 14 days to appear in culture. Infection with gram negative bacteria such as 
Escherichia coli and Klebsiella pneumoniae is less common [15, 16, 20] and probably 
occurs more commonly in shunted infants than in adults [21].
2.2 Causative organisms in EVD infection
Most cases of ventriculitis associated with EVD use are caused by staphylococci 
[13, 22, 23] but there is evidence that the proportion of gram negative bacteria 
might be increasing. Chatzi et al. [24] reported 81% of their EVD infections were 
due to MDR gram negative bacteria, mainly Acinetobacter baumannii; similar pro-
portions were reported by others [25, 26]. Another matter of concern is the increase 
in enterococcal infections, reflecting the rise of this MDR gram positive bacterium 
in general surgical site infections. Notable differences between pathogens in shunts 
and EVDs are the increasing proportion of MDR gram negative bacteria and the 
occurrence of polymicrobial infections in EVD, uncommon in shunts.
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3. Mechanisms of infection
3.1 Shunts
The main source of pathogens in shunts is the patient’s skin [8, 27]. Skin com-
mensals such as CoNS and C acnes cannot be eradicated by skin preparation, and 
they easily enter the incision where they are able to gain access to the shunt and 
possibly the ventricular system during shunt insertion. Once inside the shunt 
tubing, they attach to the surface of the silicone, after which they begin to prolifer-
ate. This proliferation is slow, because the carbon and nitrogen sources in CSF are 
insufficient to support vigorous bacterial growth, and in particular it has a very 
low iron content [28]. However, the plaques of bacteria eventually develop into a 
biofilm. Biofilms are communities of micro-organisms usually attached to a surface, 
and they are very common in device infections and in the environment. They are 
also the preferred mode of growth, rather than the very artificial growth condi-
tions applied in the laboratory. It is interesting that the first report of a biofilm in 
a medical device was from a shunt infection [29]. This early report was produced 
in response to the need to explain why antibiotic treatment, shown to be effective 
against shunt pathogens in the laboratory, was ineffective in treating shunt infec-
tions. It is now generally accepted that biofilms explain this difficulty, which is 
found in infections in other implants. The early report postulated that the biofilm 
structure was maintained by a glycosaminoglycan produced by the bacteria, and 
that antibiotics were unable to penetrate this effectively. Further research has 
confirmed the chemistry of the biofilm matrix (though it is now accepted that 
other components are present). Later studies have confirmed the presence of 
bacterial biofilms in infected shunts [30, 31]. It is now realised that most antibiot-
ics can penetrate bacterial biofilms effectively [32], but that they fail to kill the 
constituent bacteria [33–35]. This is because, when bacteria attach to a surface and 
develop a biofilm, they change their metabolism in order to conserve energy, and 
this involves downregulating all inessential functions such as cell wall synthesis, 
most protein synthesis and DNA replication. All these are target sites for common 
antibiotics, and the concentration of antibiotic needed to even reduce the numbers 
of biofilm bacteria is 500 to 1000 fold higher than that found in the laboratory [32]. 
This explains why antibiotic treatment alone is usually ineffective against biofilm 
infections.
Bacteria are shed from biofilms and this is one way in which they might reach the 
ventricular system, but bacteria also spread along the inside surfaces of the tubing, 
and they might also be introduced from the incision during shunt insertion.
3.2 EVD
EVD infections also involve biofilm formation inside the tubing as well as exter-
nally to it in the subcutaneous tunnel, and all shunt and EVD pathogens including C 
acnes and Acinetobacter baumannii produce biofilms [36, 37].
3.3 Periods of risk for infection
Generally shunts are at risk of infection only at insertion or revision, but excep-
tions are postoperative CSF leak from the incision, and later skin erosion over the 
shunt or perforation of abdominal viscus. Skin erosion might be due to pressure in a 
debilitated patient, or to poor tissue coverage and skin health in premature infants, 
or to malnutrition. The viscus most often perforated by the lower catheter is the 
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intestine. Reports in the literature often concern children and surprisingly, many 
are brought to the emergency room by parents worried that they have a parasitic 
infection, based on the lower catheter protruding from the anus [38]. Unlikely 
though this may seem, we have also seen two similar cases. There are often several 
bacteria of enteric origin, including anaerobes, in the CSF but the patients are often 
not as ill as might be expected.
It is generally agreed that the risk to shunts from bacteraemia during den-
tal treatment is extremely small and does not warrant antibiotic prophylaxis. 
Haematogenous infection in both VP and VA shunts is very uncommon.
The period of risk for EVDs is very different. Access by skin bacteria is possible 
during insertion of the EVD, but the main risk extends for the time the EVD is in 
place, and is from skin bacteria that migrate from the exit site, from interventions 




The features of infection are different in VP and VA shunts. The discharge of 
bacteria and inflammatory products from an infected VP shunt into the peritoneal 
cavity triggers a local inflammatory response that often results in obstruction of 
the outflow of CSF. Sometimes this involves the greater omentum, and a CSF-filled 
cyst is formed around the end of the shunt [39]. This inflammatory response causes 
distal-end blockage of the shunt and return of the symptoms of hydrocephalus. 
This is the main reason for the important difference in time of presentation 
between infected VP and VA shunts: VP shunt infections usually present within 
months of operation, while VA shunt infections can present years later. However, 
CSF pseudocysts can present many years after shunt insertion with no evidence of 
infection [40].
In view of the presenting symptoms in VP shunt infection being those of 
raised intracranial pressure, it is important to distinguish between a non-infected 
blockage and one arising from shunt infection. Features of VP shunt infection 
include fever, headache, vomiting and irritability, though all of these are vari-
able in consistency and can be due to non-infective obstruction. If the symptoms 
appear within 6–8 months of insertion or revision, this increases the likelihood 
of infection. If there is erythema over the catheter track then this is an important 
sign, but it is not always present. Abdominal ultrasound may show adhesions or 
cyst formation. Shunt aspiration will reveal bacteria on gram film and/or culture, 
but will not always show raised white cell count or other CSF abnormalities. In the 
absence of clear indications, there is often reluctance to aspirate the shunt due to 
concern for introduction of infection, but this risk is slight. Blood culture is usu-
ally negative. Blood C-reactive protein (CRP) is useful as it is often raised as part 
of the tissue inflammatory response. The features of VP shunt infection therefore 
include:
Presentation <6-8 months of operation
Symptoms of shunt obstruction
Erythema over the catheter track
Raised C-reactive protein
Pyrexia
Bacteria in gram stain and culture of aspirated CSF
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Gram film examination is useful even if the CSF appears to be clear to the naked 
eye, as if bacteria can be seen it can make an early diagnosis irrespective of culture 
results. If culture is negative in the presence of a positive gram film then further 
measures can be taken such as extended anaerobic culture.
As not all VP shunt infections are contracted at operation, there will be some 
resulting from skin erosion over the valve or perforation of abdominal viscus but 
these are uncommon and the diagnosis is usually obvious. Haematogenous shunt 
infections are extremely rare. “Late” infections sometimes occur, due especially 
to C acnes, but those due to Streptococcus pneumoniae, Neisseria meningitidis or 
Haemophilus influenzae are almost always community-acquired meningitis in a 
person with a shunt, not a shunt infection, and this has important implications for 
treatment.
Presentation of VA shunt infection is often also within a few months of opera-
tion but in this case it can extend to several years later, leading to the unfounded 
suspicion that these infections are not contracted at surgery. Those VA shunt infec-
tions that present after more than 1–2 years are sometimes associated with immune 
complex disease. Here, the bacterial antigen discharging from the shunt into the 
bloodstream provokes an antibody response, and eventually the concentrations of 
circulating antigen and antibody combine into insoluble complexes that are depos-
ited mainly on basement membranes [41, 42]. The skin, lungs, joints and renal 
glomerulae are particularly affected [43]. VA shunt infections can therefore present 
as chronic skin lesions (some haemorrhagic), chronic non-productive cough, swol-
len painful joints or haematuria. This often leads to initial referral to dermatology, 
respiratory medicine, rheumatology [44], orthopaedics and nephrology [45], and 
the diagnosis of shunt infection is sometimes missed or delayed. The causative 
bacteria in such cases are usually either CoNS or C acnes. Immune complex disease 
usually resolves on shunt removal.
Again aspiration of CSF from the shunt reservoir usually reveals the infect-
ing bacterium. Blood cultures are usually positive but in very longstanding cases 
the pathogen might be non-culturable, or might appear as the biofilm phenotype 
known as small colony variants (SCV) which can be difficult to identify in the 
clinical laboratory [46, 47]. Iron-unresponsive anaemia is often a feature, and 
complement C3 and C4 levels are usually low due to complement consumption. 
CRP is often normal. An antibody assay has been used to diagnose late-presenting 
VA shunt infection [48, 49].
4.2 EVD infection
Diagnosis of infection in EVDs is often difficult. Features consistent with a 
diagnosis of ventriculitis are often present in patients with traumatic brain injury 
or stroke, and fever, with raised CSF white cell count, raised CSF protein level, 
disturbance of consciousness, Glasgow Coma Score, and inflammatory markers 
such as CRP are not helpful [50, 51]. In order to overcome the problem of raised 
white blood cell counts in patients with blood in the CSF, an index has been pro-
posed, based on comparison of white cells and red cells in CSF and blood [52] but 
the number of patients in their study was small. A raised level of soluble Triggering 
Receptor Expressed on Myeloid cells (s-TREM) in CSF has been reported to be a 
reliable marker of ventriculitis even in the presence of haemorrhage [53] and this 
merits further investigation.
However, a positive culture result from CSF has been held to be the “gold stan-
dard,” yet this is fraught with problems. Many isolates are skin commensals, and 
might be either pathogens or contaminants, or might be colonising the distal parts 
of the ventricular catheter but absent from the ventricles. If a recognised pathogen 
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such as S aureus or A baumannii is isolated then this is generally taken as a reason to 
begin definitive treatment, but more than a single isolate of the same strain of CoNS 
is usually required. Isolates from broth cultures alone should usually be disregarded 
as likely contaminants, and broth cultures are generally unhelpful. Some have 
advocated daily CSF aspiration and examination [54] but this has not been found to 
be reliable in diagnosing or predicting ventriculitis [55], and has been identified as 
a risk factor for EVD infection. Therefore, in addition to a positive CSF culture, the 
Infectious Diseases Society of America (IDSA) recommendation is: “New headache, 
fever, evidence of meningeal irritation, seizures, and/or worsening mental status are 
suggestive of ventriculitis or meningitis in the setting of recent trauma or neuro-
surgery (strong, moderate evidence)” [56]. This guidance applies the need for the 
feature to be “new” and this is an important consideration in those patients already 
showing non-specific symptoms due to their underlying pathology.
5. Treatment
5.1 Shunt infections
There are several obstacles in the way of successful treatment of shunt infec-
tions. Though in most institutions, MRSA is not a common shunt pathogen, 
many CoNS are multi-resistant including to methicillin and other beta-lactam 
antibiotics. Another problem is the poor CSF penetration of most antibiotics given 
intravenously [57] so CSF levels are below the minimum bactericidal concentra-
tion (MBC). A third problem is the presence of shunt pathogens as biofilms in the 
catheter, as eradication of these requires up to 1000 times more antibiotic than the 
MBC measured in the laboratory [32]. The best chance of successful treatment of 
shunt infection is therefore shunt removal followed by a course of antibiotics and 
usually EVD before replacement with a new shunt if required [58]. This topic has 
been further confirmed by a review by James et al. [59]. A study in children showed 
88% first-time cure using shunt removal, antibiotics and EVD, a lower success rate 
with an immediate shunt replacement protocol, but only 33% success with antibiot-
ics and no shunt removal [60]. In many such studies there is also a disturbingly high 
mortality rate in those managed with shunt retention. Once the shunt is removed, 
this leaves a residue of infection in the ventricular system, and as it has arisen from 
the biofilm in the catheters it is likely to exhibit the biofilm phenotype and have a 
raised MBC. However, the problem of CSF penetration now becomes paramount. 
Ventriculitis caused by CoNS or C acnes does not give rise to vigorous inflammatory 
response [61], and this limits access of antibiotics to the CSF. Several factors apart 
from inflammation also influence the penetration of antibiotics into CSF [57]. Many 
antibiotics that could be used to treat ventriculitis fail to achieve sufficient concen-
trations in the CSF [62–64], and this has led to consideration of additional intra-
ventricular administration via EVD [65]. Such a protocol was recommended by the 
British Society for Antimicrobial Chemotherapy [66] for staphylococcal infections, 
consisting of intraventricular vancomycin 20 mg daily, and oral or intravenous (IV) 
rifampicin 300 mg twice daily (15 mg/kg daily for children). The protocol has been 
shown to reduce the risk of relapse and to shorten the course of treatment needed 
[67, 68]. However, the association of variable to low antibiotic penetration with 
clinical failure has been questioned [69], but much of the information on antibiotic 
penetration into the CSF comes from patients with meningitis, and it is accepted 
that in ventriculitis the penetration is lower, especially when staphylococci are 
involved. A general principle is that if CSF antibiotic levels that reach the MIC can 
be achieved by intravenous administration, then this is sufficient, but the MBC is 
7
Infections in CSF Shunts and External Ventricular Drainage
DOI: http://dx.doi.org/10.5772/intechopen.98910
probably more important and this needs to be 5–8 times the MIC to ensure clinical 
success [70]. It is generally agreed that intraventricular administration of vancomy-
cin is safe, irrespective of CSF levels, which can reach 100 mg/L, though some have 
advocated monitoring of CSF levels and dosage adjustment [68], which we have 
not found necessary. This is not necessarily true of all antibiotics: gentamicin CSF 
trough levels must be maintained below 5–20 mg/L [71], and betalactams should 
not be given by the intraventricular route due to neurotoxicity [72].
Though the general principle is that successful management of shunt infection 
can be best achieved by shunt removal, linezolid, an oxazolidinone antibiotic, might 
offer some prospect of retaining an infected functioning shunt due to its excellent 
CSF penetration and its anti-biofilm activity. An in vitro study has shown that 
linezolid in concentrations achievable in CSF can eradicate staphylococcal biofilms, 
including those of MRSA, from shunt catheters [73]. Linezolid gives high CSF levels 
even after oral administration [74, 75] and it has been used successfully in a small 
number of cases of shunt infection. Success has been achieved against vancomycin 
partially – resistant MRSA in shunt infection with shunt removal [76, 77]. In some 
cases it has been used without shunt removal. One case due to meticillin-resistant 
CoNS responded to oral linezolid without shunt removal after failed therapy with 
IV vancomycin and cefotaxime [78], and a further two, one due to MRSA and 
the other to meticillin-resistant CoNS, were initially unsuccessfully treated with 
IV vancomycin and ceftriaxone, but responded without shunt removal after IV 
linezolid. Further trials of this mode of management are urgently needed.
An exception to the rule that shunt removal should be the management of choice 
applies to those with a shunt who contract community-acquired meningitis, due 
to S pneumoniae, H influenzae or N meningitidis. As noted above, these are not true 
shunt infections, and the bacteria appear unable to colonise the shunt in the same 
way as other organisms. Clinical experience has shown that a conservative approach 
consisting of usual treatment for meningitis is almost always successful, and the 
patients usually recover quickly [79–83].
5.2 EVD infections
The general principles of treatment of shunt infections apply to EVD-associated 
ventriculitis, in that bacterial biofilms are involved and there may be difficulty 
in achieving sufficiently high CSF antibiotic levels during IV administration. An 
important difference from shunt infections is the much higher proportion of infec-
tions caused by gram negative bacteria, many of which are multi – drug - resistant. 
These include K pneumoniae, A baumannii and Pseudomonas aeruginosa, though the 
last are less common.
As soon as a diagnosis of certain or probable ventriculitis is made the EVD cath-
eter should be removed. Failure to remove the infected EVD catheter was identified 
as a significant risk for treatment failure and mortality [84]. Once a new EVD cath-
eter has been placed, appropriate antibiotic treatment should begin, and this should 
be guided by laboratory identification and antibiotic susceptibilities. IV colistin 
does not reliably result in sufficient CSF levels [85]. Again the question of IV or 
intraventricular administration or both arises, but the EVD makes intraventricular 
administration (IVT) easier. Recent guidelines from the Neurocritical Care Society 
[86] recommend the use of IVT “…in patients who fail to respond to IV antimicrobi-
als alone or when organisms have high MICs to antimicrobials that do not achieve 
high CSF concentrations, especially MDR organisms.” In a study of 31 cases, caused 
mainly by Enterobacter spp., Ps aeruginosa or Stenotrophomonas (Xanthomonas) 
maltophilia, the 13 cases which received IVT gentamicin as well as IV antibiotics had 
a higher cure rate and a lower relapse rate (0/13 vs. 6/18) [71]. None of these cases 
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were due to A baumannii, which is often susceptible only to colistin. In a small study 
of two groups of nine patients with ventriculitis due to A baumannii, one group 
had both IV and IVT colistin while the other had IV only [87]. CSF sterilisation was 
achieved in 100% of those having IVT therapy (vs 33%) and the five deaths due to 
ventriculitis occurred in the IV - only group but none in the IV + IVT group. Cure is 
also reported when IVT colistin is used without IV colistin [88], so avoiding some 
of the systemic toxicity. Some strains of A baumannii are now resistant to colistin, 
but there is in vitro evidence of useful synergy with rifampicin, which suppressed 
emergence of colistin resistance as well as killing of a colistin-resistant strain. A 
combination of colistin and rifampicin was effective against colistin – resistant 
strains of K pneumoniae in vitro [89]. There are a few clinical reports of synergy 
with rifampicin, and especially if the mutual protection against resistance can be 
confirmed, this might improve prospects of treatment.
6. Risk factors and prevention
6.1 Shunts
Most analyses of risks for shunt infection identify shunting below the age of 
1 year as a factor [8, 14, 90]. Young age or prematurity at shunting and intraven-
tricular haemorrhage have been identified on univariate analysis but only young age 
on multivariate analysis, suggesting that age was the factor and the other two were 
dependent factors [91]. Why this should be has been debated. The main source of 
shunt pathogens being the patient’s skin, any factor that influences this adversely 
might be expected to increase the risk. Premature infants have a high risk of intra-
ventricular haemorrhage, and they often have been in hospital separated from their 
mothers before shunting, and it has been found that their skin bacterial densities 
were significantly higher, and that their skin bacteria were more likely to be able to 
adhere to silicone [8]. Loss of close maternal contact means that the babies become 
colonised with hospital strains of staphylococci that appear to be more virulent as 
shunt pathogens.
CSF protein content at the time of shunt insertion has been suspected to be a risk 
factor for infection, but this has been discounted [92, 93] though it may indicate a 
higher risk of re-infection after treatment of an initial shunt infection [94], possibly 
suggesting an incomplete eradication of the initial infection.
Intra-operative interventions to reduce the risk of shunt infection include 
“bundles” which are widely recognised in infection control and prevention to be 
effective if correctly applied. Choux et al. [95] introduced a protocol consisting of 
a range of sixteen measures such as restricting the number of people in the operat-
ing theatre to four, shunt insertion first thing in the morning, neonates before 
older children, limiting duration of surgery to 20–40 minutes, as well as technical 
surgical stipulations regarding a no-touch technique for the shunt, haemostasis 
and wound closure. On applying this to 1197 procedures he reduced the infection 
rate to 0.17%. Similar measures have been introduced such as use of a dedicated 
neurosurgical theatre, all passage into and out of the theatre prohibited, and no 
more than seven people present. Skin preparation used two separate applications, 
and both drapes and the peritoneal catheter introducers were smeared with povi-
done iodine which was also used to irrigate the incision and the surgeon’s gloves. 
Using this protocol the infection rate was 0.57% [96]. The Hydrocephalus Clinical 
Research Network has also published protocols aimed at reducing shunt infection 
[97]. The refined protocol has eight essential steps, reduced from eleven in earlier 
versions. Results of 1935 procedures at eight centres showed an overall infection 
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rate of 6% with 77% compliance with the protocol. Infection rates differed signifi-
cantly between centres in full compliance and those which were not (5% vs. 8.7%, 
p = 0.005). Others have used similar protocols [98, 99]. One problem with these 
protocols is that they are difficult to compare, and almost none of the measures are 
evidence-based. However, this is considered acceptable in view of the usual fall in 
infection rate when they are introduced. An important aspect of bundles is men-
tioned by Choux [95] and emphasised by Choksey [96]: to be fully effective they 
must be made compulsory and violations must be detected and remedied. Though 
many components of the protocols are “common sense” measures such as rigorous 
asepsis, their main mechanism might be behavioural change in personnel, and this 
is not necessarily teachable and exportable to other institutions. Interestingly, few 
“bundles” mention the possible use of laminar flow ventilation in the OR. Choksey 
[96] used a laminar flow hood, while Pirotte [98] did not: both reduced their shunt 
infection rate to <1%. Though laminar flow ventilation was recommended for 
arthroplasty, recently several centres have reported either no benefit, or in some 
cases a small but significant increase in infection rate [100, 101].
However, certain constituent measures deserve attention. Many use antiseptics 
to either irrigate the incision or to isolate the wound skin edges [102], a measure 
suggested some time ago [103–105]. It is clear that skin bacteria enter the incision 
from this source [27, 106]. It is important that the contribution of patient skin 
bacteria is minimised by avoiding contact with skin edges by gloves, instruments 
or shunt components, and measures to isolate them might be helpful in this regard. 
Surgeons’ gloves become contaminated early in the operation and double – gloving 
is recommended so that the contaminated outer pair can be discarded before the 
shunt is handled. At this point it is advisable to rinse the gloved hands in antiseptic 
before touching the shunt, or to use a “no - touch” technique. Double gloving 
was introduced in a sequential study but without removal of the outer pair, as the 
presumption was that the source of shunt pathogens was glove perforation [107]. 
However, the diagnostic criteria in this study are in doubt as most of the “infec-
tions” were culture-negative, and the change of outer glove remains the most 
important measure.
It is important to remember that, irrespective of the antiseptic used, pre-opera-
tive skin preparation does not sterilise the skin. Much of the literature discusses the 
merits of various antiseptics but relies on skin swabs for evaluation, though most of 
the skin flora reside in the glands and follicles in the dermis [108]. When full thick-
ness skin biopsies have been used they have shown that, irrespective of the agent 
used, while the numbers of bacteria can be reduced they cannot be eradicated, and 
they will re-emerge during surgery. The numbers of bacteria required to cause an 
infection in the presence of a biomaterial such as a shunt are at least ten thousand – 
fold fewer that those needed in its absence [109]. While there is little evidence that 
chlorhexidine is better than povidone iodine it is clear that the alcohol version of 
either is superior to the aqueous version, and it is possible that the alcohol compo-
nent is the major antiseptic factor [110].
Adhesive drapes are not of proven benefit in preventing the skin bacteria from 
entering the incision, even when iodine-treated. They are, however, useful in cover-
ing the cloth drapes and providing a dry aseptic surface. Shaving of head hair is now 
accepted as unnecessary and possible a risk for infection [111], and clipping should 
be carried out with scissors if necessary, and the hair prepared as for the skin.
The use of pre-operative prophylactic antibiotics is controversial [112]. Most of 
the reports, including where infection rates are considered unacceptably high, are 
from centres using antibiotic prophylaxis. Again the issue of timely penetration of 
IV antibiotics into the CSF is important, and most studies have found ineffective 
peri-operative levels. They also do not act rapidly enough to affect the numbers 
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of skin bacteria in the incision during shunt insertion, and while this remains as a 
risk to the shunt, they might act to reduce postoperative wound infection. Intra-
operative IVT vancomycin has not been shown to reduce shunt infection rate, prob-
ably due to the slow kill rate, but an interesting finding has been reported [113]. In 
this study, when only IV antibiotics were used, the infection rate was 6.74%; when 
IVT gentamicin was added, the infection rate was similar at 5.45%; when both IVT 
gentamicin and IVT vancomycin were used together, the infection rate fell to 0.41%. 
This interesting observation needs to be confirmed.
Another approach is the use of triclosan - coated sutures [114]. Though numbers 
of patients were small, when triclosan - coated sutures were compared with plain 
sutures in a randomised controlled trial, there was a reduction in shunt infection 
rate from 21% to 4.3%. Some, but not all, infections were postoperative wound 
suppurations.
There is increasing use of topical application of vancomycin powder before 
fascial closure in spinal surgery with significant infection reduction and low toxic-
ity compared to IV vancomycin prophylaxis. The same approach has been used in 
a small uncontrolled series of shunt insertions with a reduction of shunt infection 
from 5.8% to 0% though the postoperative revision rate was unaltered [115]. The 
diagnostic criteria for shunt infection were not clear but this use of vancomycin is 
safe and effective in spine surgery and might be useful in shunt surgery.
It appears that attempts to prevent skin bacteria from accessing the shunt during 
surgery are only partly successful, and further measures are needed. Systemic 
prophylactic antibiotics are well researched but an unacceptably high infection rate 
remains. This has led to development of shunt materials intended to reduce bacte-
rial colonisation of the catheters and therefore shunt infection.
Antimicrobial shunt catheters have been available for some time. Coating the 
shunt surface with a hydrophilic material as in the Bioglide catheter is intended to 
reduce bacterial attachment, and if the catheter is soaked in a solution of antibiotic 
then this has been claimed to add to the effect. The catheters have been evaluated 
in vitro using rigorous clinically predictive tests and though they did reduce bacte-
rial attachment they were found not to be effective in preventing colonisation by 
staphylococci [116] even when soaked in gentamicin or vancomycin [117]. Clinical 
assessment [118, 119] has confirmed this. Silver in various forms has been promoted 
as a useful antimicrobial for implantable devices, but variable results have been 
reported. Shunt catheters impregnated with nanoparticulate silver, a particularly 
active form, have been marketed. Again an in vitro evaluation has found that they 
failed to prevent colonisation by staphylococci, C acnes or E coli, and this has been 
confirmed in a large randomised controlled clinical trial [6]. Silver undoubtedly has 
antibacterial activity, but the concentrations of silver ions needed are also cyto-
toxic, and silver ions combine avidly with chloride and protein. As it is likely that 
a prolonged duration of antimicrobial activity of at least a few days is required to 
prevent survival and regrowth of bacteria in shunt catheters, and as antimicrobial 
coatings are easily removed by CSF flow and obliterated by protein deposition, a 
system is needed that maintains an antimicrobial surface. One such system distrib-
utes molecules of antimicrobials throughout the silicone matrix, allowing them to 
migrate freely to replenish the surface when CSF removes molecules from there, 
so maintaining an antimicrobial surface for sufficient time, in this case for over 
40 days [120]. This system is unaffected by protein. When the clinically predic-
tive tests are applied in vitro, the antimicrobial catheters remain free of bacterial 
colonisation even after serial high - dose bacterial challenge. Clinical studies have 
demonstrated reduction in shunt infection [121] and considerable cost savings 
[122] as well as reduction in systemic antibiotic use. A large randomised controlled 
trial comparing antimicrobial, silver and plain shunts found that the antimicrobial 
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shunts gave a statistically significant reduction in shunt infections while results for 
silver-processed shunts were indistinguishable from those of plain catheters [6].
The question of whether to use prophylactic antibiotics for people with shunts 
who undergo dental treatment has been raised frequently. Studies have shown 
that the risk is negligible, and there is no evidence that bacteria of oral origin have 
caused shunt infections, whether VP or VA, after dental treatment [123]. It is likely 
that antibiotic prophylaxis used in this way treats the dental practitioner but is of no 
benefit to the patient.
6.2 EVDs
Whether risks of infection are different if the EVD is inserted in the intensive 
care unit or the operating room (OR) is debatable. In one study there were fewer 
infections in those inserted in the OR but this difference was not statistically sig-
nificant [124]. While the OR might offer a more controllable aseptic environment, 
transfer of acutely ill patients to the OR for this purpose might pose additional 
risks [125].
Periprocedural prophylactic antibiotics are commonly used. However, many 
centres use prolonged antibiotic prophylaxis throughout the EVD use. Flibotte et al. 
[126] used either nafcillin or vancomycin but noted that most infections were still 
due to gram positive pathogens, and that their use of prolonged nafcillin appeared 
to lead to an increase in resistance to this antibiotic. Wong and Poon [127] reported 
a comparison of two regimens for prolonged prophylaxis but did not comment on 
the influence on resistance, but a later study by the same authors [128] using the 
same regimen found three cases of pseudomembranous colitis due to Clostridioides 
difficile, one of whom required total colectomy. A similar experience was reported 
[129] reducing the number of C difficile infections in the ICU from 19 to 5 by chang-
ing the antibiotic prophylaxis regimen from prolonged to peri-procedural with no 
change in ventriculitis rate. Antimicrobial impregnated EVD catheters were used in 
both phases of both these studies [128, 129]. In another study comparing prolonged 
and peri-procedural antibiotics there was no difference in infection rate, the differ-
ence being a saving of $80,000 a year in drug costs [130]. Murphy et al. [131] also 
compared a period when prolonged antibiotics were used with a period where only 
periprocedural antibiotics were given; in both periods antimicrobial EVD catheters 
were used. The infection rate in the periprocedural-only period actually fell from 
1.35/1000 catheter days to 0.54/1000 catheter days, though this was not statisti-
cally significant. Remarkably, there was a significantly higher rate of bloodstream 
infections (BSI) and pneumonia (VAP) in the prolonged – antibiotics period, and 
the drug cost for treating these infections were $155,253 but there were no cases of 
BSI or VAP in the second periprocedural - only period.
Antimicrobial catheters have been developed for EVDs as for shunts, though 
there have been fewer clinical trials. The hydrophilic-coated catheters intended 
to reduce infection by preventing bacterial attachment have already been dis-
cussed; these have not been successful. Silver-processed catheters have shown 
non-significant results in some clinical studies [132–135]. One three-phase retro-
spective/ sequential study showed that introduction of silver-processed catheters 
reduced the infection rate from 3.8% to zero, though due to small numbers this 
was not statistically significant [136]. A randomised prospective controlled trial 
comparing silver-processed with plain catheters has reported a significant reduc-
tion in ventriculitis from a very high rate of 21.4% to 12.3%, a fall that just met 
statistical significance p = 0.0427 [137]. A thorough assessment of the value of 
silver-processed EVD catheters [138] has found no significant overall difference in 
infection rate in a meta-analysis but did identify a statistically significant reduction 
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in infection due to gram positive bacteria (6.7–2%, p = 0.002). The conclusion was 
that silver-processed catheters require further evaluation, and that they have no 
activity against gram negative bacteria. This was confirmed in vitro using the same 
rigorous clinically – predictive testing used for shunts, when silver-processed EVD 
catheters were found to show a weak activity against S epidermidis but none against 
gram negative bacteria [139].
An antibiotic-impregnated catheter containing rifampicin and minocycline 
(VentriClear, Cook Inc) is available in USA, and Bactiseal (Codman Integra Life 
Sciences) that contains rifampicin and clindamycin, produced by a different 
process, is available worldwide. A significant (p = 0.002) reduction in ventriculitis 
has been reported when VentriClear catheters were used, from 9.4% to 1.3% [140]. 
Harrop et al. [12] carried out a five -phase prospective cohort study. Phase I, the 
baseline, showed a rate of 6.7%, and the introduction of a standardised protocol 
in Phase II did not reduce this (8.2%). However, in Phase III the Bactiseal catheter 
was included, and the infection rate fell to 1% (p = 0.0005). This catheter gave an 
unacceptable rate of occlusion and its use was discontinued, and reversion to the 
Phase II protocol showed a return to a 7.6% rate. In Phase V, the VentriClear catheter 
was introduced and the ventriculitis rate again fell to 0.9% (p = 0.0001). Though 
a sequential cohort study, this provided strong evidence that both antimicrobial 
catheters were effective. This was confirmed by a comparison of VentriClear with 
Bactiseal [141] using alternating 3-month periods when 129 patients received either 
a VentriClear or a Bactiseal catheter. No cases of ventriculitis were recorded in the 
study, showing that both were equally effective in this study. No excess of occlusion 
was recorded with either catheter. A series involving historical controls found a 
reduction of ventriculitis from 15% in plain catheters to 5% in Bactiseal catheters 
but this failed to reach statistical significance [142]. Bactiseal was compared with 
plain EVD catheters in an interesting study in which CSF samples were taken every 
2 days, and if culture-positive, irrespective of clinical evidence, the catheter was 
changed and 10 days of intraventricular antibiotics were given [143]. In this study 
there were no cases of clinical infection in either group. As with shunts, there is no 
evidence that antimicrobial-impregnated EVD catheters increase the risk of bacte-
rial resistance, and in reducing the need for systemic antibiotics for prophylaxis and 
treatment of infections they are likely to contribute to reduction of antimicrobial 
resistance generally. This has been underlined by three studies in which prolonged 
systemic antibiotic prophylaxis for EVD has been compared with use of the Bactiseal 
catheter. In two studies the antimicrobial catheter gave equivalent protection against 
ventriculitis but avoided the serious risk of C difficile infection [128, 129], a known 
consequence of over-use of antibiotics. In the third study [131] the Bactiseal EVD 
catheter was used but in one group, prolonged antibiotic prophylaxis were added. 
There was no difference in ventriculitis rate between the two groups, but there was 
a significantly higher rate of BSI and VAP, requiring further courses of antibiotics 
for treatment, again contributing to antimicrobial resistance. While good qual-
ity randomised controlled trials are needed for antimicrobial - impregnated EVD 
catheters, the studies so far strongly suggest that they can reduce the incidence of 
ventriculitis by gram positive bacteria, but there is currently no EVD catheter avail-
able that protects against gram negative bacteria, which are increasing in frequency 
and importance. An experimental antimicrobial EVD catheter that can protect 
against colonisation by MDR gram negative bacteria including A baumannii has 
been developed but is not yet clinically available [144].
There is general agreement that the EVD catheter must be tunnelled subcutane-
ously for approximately 5 cm away from the burr hole, but some prefer to tunnel for 
much longer. When the exit site was placed in the lower chest or upper abdomen, no 
infections were reported in the first 16 days. In those 45 requiring EVD for longer, 
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four developed ventriculitis [145]. In a study using a long tunnel of at least 20 cm an 
infection rate significantly lower than those reported in the literature using con-
ventional tunnels was noted, though an antimicrobial EVD catheter was also used 
[146]. However, Leung et al. [147] found no advantage in a longer tunnel.
The infection rate for EVDs is said to rise with duration of use, though this is 
sometimes contested. The duration of EVD use has frequently been identified as 
a risk factor for infection. As the increase in infection appears to begin after about 
5 days, suggestions have been made that changing the EVD catheter at this stage 
might avoid the subsequent rise in infection rate [148]. However, this practice has 
been shown not to help [149, 150] and might increase the risk [151]. The risk for 
ventriculitis increases in most studies until about 10–12 days then levels off. The 
message is that the EVD should be removed as soon as possible when no lon-
ger needed.
EVD pathogens are more varied, and more likely to be MDR gram negative 
bacteria than those found in shunts. They might originate on the patient’s body 
surfaces, ears and respiratory tract as broad-spectrum antibiotics given for chest 
infections and other purposes promote colonisation of these sites with such organ-
isms. The intensive care environment is often a source of such bacteria due to the 
throughput of very sick patients and heavy use of antibiotics. This environment 
includes all inanimate surfaces, textiles and water sources [152, 153]. The EVD 
must be managed with careful attention to aseptic technique, and breaches of the 
system should be avoided unless absolutely necessary. This includes CSF sampling 
for monitoring purposes. The practice of daily CSF sampling is said to enable 
early diagnosis of infection [154, 155], but represents a risk for introduction of 
infection, and CSF sampling is best confined to cases where there is a suspicion of 
infection [155].
As with shunts, the introduction of “bundles” has usually been associated with 
a reduction in infection rate. Korinek et al. [156] developed a bundle protocol and 
introduced a violation score to monitor it. Their ventriculitis rate fell from 9.9% 
to 4.6%, and the most significant factors in infected patients were CSF leak and pro-
tocol violation, which in the infected cases was 4 times higher p < 0.0001. The value 
of this approach was also demonstrated by others with a significant fall in infection 
rate [155, 157]. Importantly, the bundle approach should include full involvement 
of all personnel involved and should be monitored and regular feedback given on 
violations and infection rates. Again, not all of the constituents of the bundle are 
evidence – based and they vary between reports, but the behaviour change brought 
about by this approach is the most important factor.
7. Conclusions
Infection in shunting and EVD is often devastating. Prevention is paramount 
and a greater understanding of the science and the risk factors should inform more 
effective measures including surgical practice and OR discipline. Antimicrobial 
catheters are useful in reducing infection in shunts and EVDs, but the problem of 
gram negative infection needs to be addressed. There should be no delay in institut-
ing effective treatment, including removal of hardware and ensuring adequate 
levels of antibiotics. Successful first pass treatment should be the goal. Treatment 
without hardware removal, using relatively new antibiotics, should be thoroughly 
investigated in view of the potential benefits.
Importantly, the contribution of overuse or misuse of antibiotics to the increas-
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